The discovery of an “Achilles heel” in a type of gut bacteria that causes intestinal inflammation in patients with Crohn’s disease may lead to more targeted therapies for the difficult-to-treat disease, according to researchers at Weill Cornell Medicine and NewYork-Presbyterian.

In a study published Feb. 5 in Cell Host and Microbe, the investigators showed that patients with Crohn’s disease have an overabundance of a type of gut bacteria called adherent-invasive Escherichia coli (AIEC), which promotes inflammation in the intestine. Their experiments revealed that a metabolite produced by the bacteria interacts with immune system cells in the lining of the intestine, triggering inflammation.

Interfering with this process – by either reducing the bacteria’s food supply or eliminating a key enzyme in the process – relieved gut inflammation in an animal model of Crohn’s disease.

“The study reveals a therapeutically targetable weak point in the bacteria,” said senior author Dr. Randy Longman, M.D. ’07, associate professor of medicine in the Division of Gastroenterology and Hepatology and director of the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

To find this “Achilles heel,” Longman and his colleagues – including Dr. Ellen Scherl and assistant professor Chun-Jun Guo at Weill Cornell Medicine; Gretchen Diehl, associate member at Memorial Sloan Kettering; and Kenneth Simpson, professor of small animal medicine at the Cornell College of Veterinary Medicine – targeted a process the AIEC bacteria uses to convert a byproduct of sugar fermentation in the gut to grow.

Specifically, the AIEC uses 1,2-propanediol, a byproduct of the breakdown of a type of sugar called fucose that is found in the lining of the intestines. When the AIEC converts 1,2-propanediol, it produces propionate, which the study showed interacts with a type of immune system cell called mononuclear phagocytes that are also found in the lining of the gut. This sets off a cascade of inflammation.

Next, the investigators genetically engineered AIEC bacteria to lack a key enzyme in this process called propanediol dehydratase. Without it, the bacteria did not set off a cascade of inflammation in the animal model of Crohn’s disease.

Reducing the available supply of fucose in the animal’s gut also reduced inflammation.

“Changing one metabolic pathway in one type of bacteria can have a big impact on intestinal inflammation,” said co-lead author Monica Viladomiu, a postdoctoral associate in medicine in the Division of Gastroenterology and Hepatology and in the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine.

The discovery could lead to better treatments for Crohn’s disease, a type of inflammatory bowel disease that affects more than 4 million people worldwide. Currently, patients with Crohn’s disease are often treated with antibiotics, which can kill both beneficial and harmful bacteria causing unwanted side effects. But treatments that precisely target the inflammatory cascade discovered by Dr. Longman and colleagues might help reduce inflammation while preserving beneficial bacteria.

“If we can develop small molecule drugs that inhibit propanediol dehydratase or use dietary modifications to reduce the availability of fucose, we may be able to reduce intestinal inflammation in patients with Crohn’s disease with fewer side effects,” said Longman, who’s also a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease.

One of the next steps for the team will be testing potential treatments. They also plan to study the potential role of an enzyme called fucosyltransferase 2 in protecting the gut against this inflammatory cascade.

The study’s other co-lead author is Maeva Metz, a Weill Cornell Medicine Graduate School of Medical Sciences doctoral candidate in the Longman laboratory.

Bridget Kuehn is a freelance writer for Weill Cornell Medicine.